INFLUENZA VACCINES MARKET ANALYSIS

Key Developments

• On March 06, 2024, CSL Seqirus, a global leader in public health protection, announced that it is fully prepared to deliver its influenza vaccine portfolio for the 2024/25 season in the U.S., based on the trivalent strains recommended by the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC).
• On February 15, 2024 Osivax, a biopharmaceutical company, stated that the first person had been vaccinated in its new Phase 1 study (NCT06128382) of OVX033, a broad-spectrum sarbecovirus vaccine candidate. The single-center trial is a randomized, double-blind, placebo-controlled Phase 1 clinical investigation to evaluate the safety and immunogenicity of OVX033 at three dose levels (100 µg, 250 µg, and 500 µg).
• In October 2023, Pfizer Inc., a pharmaceutical and biotechnology company, and BioNTech SE, a biotechnology company, announced positive topline results from a Phase 1/2 study (NCT05596734) that assessed the safety, tolerability, and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 in healthy adults aged 18 to 64.
• In October 2023, AstraZeneca, a science-led biopharmaceutical company, announced that the U.S. FDA had accepted its Supplemental Biologics License Application (sBLA) for the approval of a self- or caregiver-administered option for FluMist Quadrivalent, a needleless nasal spray. If approved, FluMist will be the first flu vaccine that may be self-administered by qualified patients or caregivers, providing another way to get vaccinated against influenza.